Elevated Pharma · Research & evidence
Research, in context.
Explore 24 references across 8 research areas. Each brings together key studies, current FDA status, evidence limits and the original sources. Updated November 7, 2026.
What do the evidence labels mean?
The label describes the sources in each reference. Open a record to read the evidence limits and follow the original links.
- Clinical or human research
- Research involving people. Findings belong to the substance, population and study described.
- Preclinical literature
- Cell, laboratory or animal research. This is a different evidence level from human research.
- Drug or biologic labeling
- Published labeling for a particular regulated product. That status belongs to that product.
- Biochemical or analytical reference
- Information about identity, composition or analysis. It does not establish a personal outcome.
- Component sources only
- Sources concern individual ingredients. The blend itself has no combined evidence conclusion assigned here.
- Identity review required
- The material name leaves a composition or identity question that needs documentation.
Research summaries & sources
24 references shown
RetatrutideTriple-receptor research · GLP-1, GIP & glucagonPhase 3 clinical research 10 key studiesResearch & sources
Retatrutide is an investigational peptide studied at the GLP-1, GIP and glucagon receptors. Phase 3 trials have been reporting since May 2026, and the sponsor plans to file for FDA approval in early 2027.
- Research summary
- Published phase 3 trials now include TRIUMPH-1 (NEJM, 2026), TRIUMPH-2 and TRANSCEND-T2D-1 (Lancet, 2026), alongside the 2023 phase 2 trial. Sponsor-reported results add TRIUMPH-3, TRIUMPH-4 and a head-to-head comparison with semaglutide.
- Evidence limits
- Trial results describe the sponsor’s investigational drug in the studied populations. They do not establish the identity, quality or safety of any independently sourced material.
- U.S. status · November 7, 2026
- Investigational. Lilly states retatrutide is legally available only to participants in its clinical trials and plans to submit it for FDA review in the first quarter of 2027.
Identity & technical details
- Primary name
- Retatrutide
- Also indexed as
- LY3437943
Key studies
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.N Engl J Med · 2026 · Human RCT · phase 3
- Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet · 2026 · Human RCT · phase 3
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1).Lancet · 2026 · Human RCT · phase 3
TirzepatideDual-receptor research · GLP-1 & GIPFDA-labeled drug reference 9 key studiesResearch & sources
Tirzepatide is a dual GIP and GLP-1 receptor agonist and the active ingredient in two FDA-approved medicines, Mounjaro and Zepbound. Its trial record is one of the largest of any peptide in this library.
- Research summary
- The SURPASS (type 2 diabetes) and SURMOUNT (obesity) phase 3 programs are published, including head-to-head trials against semaglutide, a weight-maintenance trial and a three-year diabetes-prevention analysis.
- Evidence limits
- Approval and trial results apply to the approved products as labeled. They do not transfer to an unlabeled research material or another supplier’s product.
- U.S. status · November 7, 2026
- FDA-approved as Mounjaro (type 2 diabetes, including children 10 and older since late 2025) and Zepbound (chronic weight management and obstructive sleep apnea). FDA approved a multi-dose Zepbound KwikPen in February 2026.
Identity & technical details
- Primary name
- Tirzepatide
- Also indexed as
- LY3298176
- Molecular formula
- C225H348N48O68
- Molecular mass
- 4813 g/mol
- PubChem CID
- 166567236
Key studies
- Tirzepatide Once Weekly for the Treatment of Obesity.N Engl J Med · 2022 · Human RCT · phase 3
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.N Engl J Med · 2025 · Human RCT · phase 3
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med · 2021 · Human RCT · phase 3
AOD9604Growth-hormone fragment · Metabolic researchPreclinical literature / FDA review 4 key studiesResearch & sources
AOD9604 is a modified fragment of the C-terminal end of human growth hormone, studied in mouse metabolic models and in early human obesity trials that did not lead to approval.
- Research summary
- Published work includes mouse fat-metabolism studies, a rabbit joint model and doping-detection methods.
- Evidence limits
- Mouse findings do not establish human effectiveness or safety.
- U.S. status · November 7, 2026
- Not FDA-approved. FDA has cited insufficient safety information for compounded AOD-9604.
Identity & technical details
- Primary name
- AOD9604
- Also indexed as
- AOD-9604 / Modified growth hormone C-terminal fragment
- Molecular formula
- C78H123N23O23S2
- Molecular mass
- 1815.1 g/mol
- PubChem CID
- 71300630
Key studies
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.Int J Obes Relat Metab Disord · 2001 · Animal study
- Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.Ann Clin Lab Sci · 2015 · Animal study
- AOD-9604 Metabolic.Curr Opin Investig Drugs · 2004 · Review
5-Amino-1MQSmall molecule · Cellular metabolism researchPreclinical literature 4 key studiesResearch & sources
5-Amino-1MQ is a small-molecule inhibitor of the enzyme NNMT, not a peptide. Its published record is small and preclinical.
- Research summary
- Enzyme, cell and mouse studies of NNMT inhibition, plus a rat pharmacokinetic method paper. No human trial was found.
- Evidence limits
- The free cation and the iodide salt have different formulas and masses and are not interchangeable.
- U.S. status · November 7, 2026
- Not FDA-approved. No human safety conclusion or permitted-use claim is made.
Identity & technical details
- Primary name
- 5-Amino-1MQ
- Also indexed as
- 5-Amino-1-methylquinolinium / 5-Amino-1-methylquinolinium iodide
- Molecular formula
- C10H11IN2
- Molecular mass
- 286.11 g/mol
- PubChem CID
- 66522933
Key studies
- Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.Biochem Pharmacol · 2018 · Animal and cell study
- Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase.J Med Chem · 2017 · Chemistry study
- Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.Sci Rep · 2022 · Animal study
GHK-CuCopper peptide · Skin researchPreclinical literature 6 key studiesResearch & sources
GHK-Cu is the copper complex of the tripeptide glycyl-histidyl-lysine. It is widely studied in skin and wound models and used in topical cosmetics.
- Research summary
- Evidence includes laboratory and animal wound studies, gene-expression work and small topical human studies. A 2026 review focuses on copper speciation and formulation quality.
- Evidence limits
- Preclinical findings do not establish clinical benefit, and topical findings do not transfer to injected material.
- U.S. status · November 7, 2026
- FDA removed injectable GHK-Cu from its Category 2 compounding list in April 2026 and scheduled it for advisory-committee review before the end of February 2027. It is not covered by the October 2026 HHS interim policy.
Identity & technical details
- Primary name
- GHK-Cu
- Also indexed as
- Copper tripeptide-1 / Copper glycyl-L-histidyl-L-lysine
- Sequence
- Gly-His-Lys
- Molecular formula
- C14H21CuN6O4-
- Molecular mass
- 400.9 g/mol
- PubChem CID
- 139035031
Key studies
- In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds.J Clin Invest · 1993 · Animal study
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.Arch Facial Plast Surg · 2006 · Human RCT
- GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap.Pharmaceutics · 2026 · Review
KPVThree-amino-acid peptide · Skin researchPreclinical literature 6 key studiesResearch & sources
KPV is the tripeptide lysine-proline-valine, the C-terminal end of alpha-MSH. It is studied in cell and mouse models of inflammation, especially colitis.
- Research summary
- Published work is preclinical: colitis models in mice, skin and macrophage cell studies, and new oral delivery systems. No completed human trial was found.
- Evidence limits
- Cell and animal findings are not human outcome evidence.
- U.S. status · November 7, 2026
- FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
Identity & technical details
- Primary name
- KPV
- Also indexed as
- Lys-Pro-Val / Lysine-proline-valine
- Sequence
- Lys-Pro-Val
- Molecular formula
- C16H30N4O4
- Molecular mass
- 342.43 g/mol
- PubChem CID
- 125672
Key studies
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.Gastroenterology · 2008 · Animal and cell study
- Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers.Sci Adv · 2026 · Animal study
- The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials.Cells · 2023 · Review
BPC-157Skin, tendon & connective-tissue modelsPreclinical literature / FDA review 8 key studiesResearch & sources
BPC-157 is a synthetic 15-residue peptide studied mostly in rodent models of tissue and gut injury. In 2026 it moved from FDA’s restricted list to an HHS interim compounding policy, though it remains unapproved.
- Research summary
- The record is mainly preclinical. Human data are limited to small case series; two 2026 systematic reviews and an orthopaedic review conclude that controlled human evidence is lacking.
- Evidence limits
- Preclinical findings do not establish human effectiveness or safety, and evidence for one compound does not transfer to a blend.
- U.S. status · November 7, 2026
- FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention; nominated for ulcerative colitis). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
Identity & technical details
- Primary name
- BPC-157
- Also indexed as
- Body protection compound 157
- Molecular formula
- C62H98N16O22
- Molecular mass
- 1419.5 g/mol
- PubChem CID
- 9941957
Key studies
- Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety.Acta Orthop Belg · 2026 · Systematic review
- Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500.J Am Acad Orthop Surg · 2026 · Review
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.HSS J · 2025 · Systematic review
TB-500Peptide fragment · Cell movement & tissue modelsIdentity review required 6 key studiesResearch & sources
FDA defines TB-500 as the seven-residue thymosin beta-4 fragment LKKTETQ with N-terminal acetylation. It is not full-length thymosin beta-4, and most published research is on the full-length protein.
- Research summary
- Human trials studied full-length thymosin beta-4 (for example in venous ulcers). FDA reported finding no published in-vivo wound studies for the defined fragment itself.
- Evidence limits
- Full-length thymosin beta-4 evidence cannot be assigned to TB-500 without exact structural documentation.
- U.S. status · November 7, 2026
- FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention; the nominated substance was the fragment). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
Identity & technical details
- Primary name
- TB-500
- Also indexed as
- N-acetyl-LKKTETQ / Thymosin beta-4 fragment 17-23
- Sequence
- N-acetyl-LKKTETQ
Key studies
- Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500.J Am Acad Orthop Surg · 2026 · Review
- A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.Ann N Y Acad Sci · 2010 · Human RCT · phase 1
- The effect of thymosin treatment of venous ulcers.Ann N Y Acad Sci · 2010 · Human RCT · phase 2
GLOWBPC-157 + GHK-Cu + TB-500Component sources only 3 componentsResearch & sources
GLOW is a blend name for BPC-157 + GHK-Cu + TB-500. It has no single molecular identity; each component has its own reference and evidence record.
- Research summary
- No study of this exact combination was found. Read each component’s key studies separately.
- Evidence limits
- Evidence for one component does not establish the stability, compatibility, safety or performance of the mixture.
- U.S. status · November 7, 2026
- FDA’s 2026 advisory review evaluated single substances only. No mixture was evaluated, and component evidence does not establish how a blend behaves.
Identity & technical details
- Primary name
- GLOW
- Also indexed as
- GLO / BPC-157 + GHK-Cu + TB-500 / Body Protection Complex / Three-component source-list group
- Components
- BPC-157 + GHK-Cu + TB-500
Components
- BPC-157 research reference8 key studies
- GHK-Cu research reference6 key studies
- TB-500 research reference6 key studies
KLOWGHK-Cu + TB-500 + BPC-157 + KPVComponent sources only 4 componentsResearch & sources
KLOW is a blend name for GHK-Cu + TB-500 + BPC-157 + KPV. It has no single molecular identity; each component has its own reference and evidence record.
- Research summary
- No study of this exact combination was found. Read each component’s key studies separately.
- Evidence limits
- Evidence for one component does not establish the stability, compatibility, safety or performance of the mixture.
- U.S. status · November 7, 2026
- FDA’s 2026 advisory review evaluated single substances only. No mixture was evaluated, and component evidence does not establish how a blend behaves.
Identity & technical details
- Primary name
- KLOW
- Also indexed as
- GHK-Cu + TB-500 + BPC-157 + KPV / KLOW source-list label
- Components
- GHK-Cu + TB-500 + BPC-157 + KPV
Components
- GHK-Cu research reference6 key studies
- TB-500 research reference6 key studies
- BPC-157 research reference8 key studies
- KPV research reference6 key studies
WolverineBPC-157 + TB-500Component sources only 2 componentsResearch & sources
Wolverine is a blend name for BPC-157 + TB-500. It has no single molecular identity; each component has its own reference and evidence record.
- Research summary
- No study of this exact combination was found. Read each component’s key studies separately.
- Evidence limits
- Evidence for one component does not establish the stability, compatibility, safety or performance of the mixture.
- U.S. status · November 7, 2026
- FDA’s 2026 advisory review evaluated single substances only. No mixture was evaluated, and component evidence does not establish how a blend behaves.
Identity & technical details
- Primary name
- Wolverine
- Also indexed as
- BPC-157 + TB-500 / Wolverine stack / Two-component source-list group
- Components
- BPC-157 + TB-500
Components
- BPC-157 research reference8 key studies
- TB-500 research reference6 key studies
KPV + GHK-CuKPV + GHK-CuComponent sources only 2 componentsResearch & sources
KPV + GHK-Cu is a blend name for KPV + GHK-Cu. It has no single molecular identity; each component has its own reference and evidence record.
- Research summary
- No study of this exact combination was found. Read each component’s key studies separately.
- Evidence limits
- Evidence for one component does not establish the stability, compatibility, safety or performance of the mixture.
- U.S. status · November 7, 2026
- FDA’s 2026 advisory review evaluated single substances only. No mixture was evaluated, and component evidence does not establish how a blend behaves.
Identity & technical details
- Primary name
- KPV + GHK-Cu
- Also indexed as
- Two-component source-list group
- Components
- KPV + GHK-Cu
Components
- KPV research reference6 key studies
- GHK-Cu research reference6 key studies
HCGReproductive hormone researchFDA-labeled biologic reference 2 key studiesResearch & sources
Human chorionic gonadotropin (hCG) is a glycoprotein hormone with alpha and beta subunits. FDA-labeled hCG products state potency in USP units rather than by mass.
- Research summary
- The literature spans reproductive endocrinology, diagnostics and pharmacology. Recent human work compares recombinant and urinary hCG.
- Evidence limits
- Mass alone does not establish hCG potency or equivalence between products.
- U.S. status · November 7, 2026
- FDA-labeled hCG drug products exist and are dosed in USP units. This reference does not describe or imply any Elevated Pharma product.
Identity & technical details
- Primary name
- HCG
- Also indexed as
- Human chorionic gonadotropin / hCG
Key studies
- Single and multi-dose pharmacology of recombinant and urinary human chorionic gonadotrophin in men.Clin Endocrinol (Oxf) · 2024 · Human RCT
- Hyperglycosylated hCG, a review.Placenta · 2010 · Review
GHRP-2Growth-hormone pathway researchHuman research literature 6 key studiesResearch & sources
GHRP-2 (pralmorelin) is a synthetic hexapeptide growth-hormone secretagogue. It has been used as a diagnostic test agent in Japan and studied in human endocrine research.
- Research summary
- Human studies cover pharmacokinetics in children, GH release in critical illness and diagnostic testing of the pituitary.
- Evidence limits
- Endocrine response data do not provide a general safety conclusion or establish an independently sourced material’s identity.
- U.S. status · November 7, 2026
- Not FDA-approved. GHRP-2 was not on FDA’s 2026 compounding advisory agendas.
Identity & technical details
- Primary name
- GHRP-2
- Also indexed as
- Growth hormone-releasing peptide 2 / Pralmorelin
- Molecular formula
- C45H55N9O6
- Molecular mass
- 818 g/mol
- PubChem CID
- 6918245
Key studies
- Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children.J Clin Endocrinol Metab · 1998 · Human clinical study · phase 1
- Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.Eur J Endocrinol · 1999 · Human RCT
- Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder.J Endocr Soc · 2022 · Human clinical study
TesamorelinGrowth-hormone pathway researchFDA-labeled drug reference 6 key studiesResearch & sources
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone and the active ingredient in FDA-approved Egrifta, used for excess abdominal fat in people with HIV.
- Research summary
- Randomized trials in people with HIV cover visceral fat, fatty liver and neurocognition; smaller studies examine people without HIV.
- Evidence limits
- Approval of a prescription product does not transfer to an unlabeled research material.
- U.S. status · November 7, 2026
- FDA-approved as Egrifta SV and Egrifta WR for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Prescribing information is the controlling source.
Identity & technical details
- Primary name
- Tesamorelin
- Also indexed as
- TH9507
- Molecular formula
- C221H366N72O67S
- Molecular mass
- 5136 g/mol
- PubChem CID
- 16137828
Key studies
- Metabolic effects of a growth hormone-releasing factor in patients with HIV.N Engl J Med · 2007 · Human RCT · phase 3
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.Lancet HIV · 2019 · Human RCT
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.J Infect Dis · 2025 · Human RCT · phase 2
IpamorelinGrowth-hormone pathway researchHuman research literature 5 key studiesResearch & sources
Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue, first described in 1998 as selective for growth hormone release.
- Research summary
- Human data are limited to pharmacokinetic modeling in volunteers and one phase 2 trial in postoperative ileus.
- Evidence limits
- A small clinical literature does not establish broad safety or effectiveness.
- U.S. status · November 7, 2026
- Not FDA-approved. Ipamorelin was not on FDA’s 2026 compounding advisory agendas.
Identity & technical details
- Primary name
- Ipamorelin
- Also indexed as
- NNC 26-0161
- Molecular formula
- C38H49N9O5
- Molecular mass
- 711.9 g/mol
- PubChem CID
- 9831659
Key studies
- Ipamorelin, the first selective growth hormone secretagogue.Eur J Endocrinol · 1998 · Animal study
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharm Res · 1999 · Human clinical study
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.Int J Colorectal Dis · 2014 · Human RCT · phase 2
SermorelinGrowth-hormone pathway researchHuman research literature 5 key studiesResearch & sources
Sermorelin is a synthetic 29-residue analog of the active end of growth-hormone-releasing hormone, GHRH(1-29). It was previously marketed in the U.S. as Geref.
- Research summary
- Human endocrine studies used GHRH(1-29) to test pituitary growth-hormone response; recent literature focuses on detection methods and sports use.
- Evidence limits
- A base-compound record does not establish acetate content, purity or potency of a specific material.
- U.S. status · November 7, 2026
- No current FDA-approved sermorelin product is marketed. It was not on FDA’s 2026 compounding advisory agendas.
Identity & technical details
- Primary name
- Sermorelin
- Also indexed as
- Sermorelin acetate / GHRH(1-29) analog
- Molecular formula
- C149H246N44O42S
- Molecular mass
- 3357.9 g/mol
- PubChem CID
- 16132413
Key studies
- Low-dose growth hormone-releasing hormone tests: a dose-response study.Eur J Endocrinol · 1994 · Human RCT
- Acute effects of cortisone acetate on growth hormone response to growth hormone-releasing hormone in normal adult subjects.Acta Endocrinol (Copenh) · 1990 · Human RCT
- Outcome of growth hormone therapy in children with growth hormone deficiency showing an inadequate response to growth hormone-releasing hormone.Endocrine · 2001 · Human clinical study
SelankNervous-system & cognition researchPreclinical and analytical literature 6 key studiesResearch & sources
Selank is a synthetic heptapeptide based on tuftsin. Most of its literature comes from Russian research groups, with a few small clinical studies in anxiety.
- Research summary
- Animal work covers anxiety, stress and memory models; small Russian clinical studies examine anxiety disorders.
- Evidence limits
- Small, mostly non-Western studies do not establish human safety or effectiveness by current standards.
- U.S. status · November 7, 2026
- Not FDA-approved. Selank was not on FDA’s 2026 compounding advisory agendas.
Identity & technical details
- Primary name
- Selank
- Also indexed as
- Thr-Lys-Pro-Arg-Pro-Gly-Pro
- Sequence
- Thr-Lys-Pro-Arg-Pro-Gly-Pro
- Molecular formula
- C33H57N11O9
- Molecular mass
- 751.9 g/mol
- PubChem CID
- 11765600
Key studies
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia.Zh Nevrol Psikhiatr Im S S Korsakova · 2008 · Human clinical study
- A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders.Zh Nevrol Psikhiatr Im S S Korsakova · 2014 · Human clinical study
- Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.Behav Neurol · 2017 · Animal study
SemaxNervous-system & cognition researchPreclinical and analytical literature 6 key studiesResearch & sources
Semax is a synthetic heptapeptide derived from ACTH(4-10). It is registered as a medicine in Russia and studied mainly in stroke and nervous-system models.
- Research summary
- Animal studies cover stroke, spinal cord injury and Alzheimer’s models; Russian clinical studies examine stroke recovery but are mostly not placebo-controlled.
- Evidence limits
- The cited research does not establish an FDA-approved use or a human safety conclusion.
- U.S. status · November 7, 2026
- FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 24, 2026 (recommended). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
Identity & technical details
- Primary name
- Semax
- Also indexed as
- Met-Glu-His-Phe-Pro-Gly-Pro
- Sequence
- Met-Glu-His-Phe-Pro-Gly-Pro
- Molecular formula
- C37H51N9O10S
- Molecular mass
- 813.9 g/mol
- PubChem CID
- 9811102
Key studies
- The efficacy of semax in the treatment of patients at different stages of ischemic stroke.Zh Nevrol Psikhiatr Im S S Korsakova · 2018 · Human clinical study
- The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer’s Disease.Acta Naturae · 2025 · Animal study
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.Br J Pharmacol · 2025 · Animal study
DSIPSleep-related peptide researchLimited human literature 4 key studiesResearch & sources
Delta sleep-inducing peptide (DSIP, emideltide) is a nonapeptide isolated in the 1970s. Small human sleep studies from the 1980s and 1990s reported mixed results.
- Research summary
- Early isolation work defined the sequence; small clinical studies in insomnia found weak or inconsistent effects.
- Evidence limits
- The limited, mixed human literature does not establish benefit or safety.
- U.S. status · November 7, 2026
- FDA’s compounding advisory committee voted 7–6 (one abstention) against adding emideltide (DSIP) to the 503A bulks list on July 24, 2026, the only one of seven peptides it turned down. It is not covered by the October 2026 HHS interim policy.
Identity & technical details
- Primary name
- DSIP
- Also indexed as
- Delta sleep-inducing peptide / DSIP / Emideltide
- Sequence
- Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
- Molecular formula
- C35H48N10O15
- Molecular mass
- 848.8 g/mol
- PubChem CID
- 68816
Key studies
- The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide.Pflugers Arch · 1978 · Biochemistry
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.Neuropsychobiology · 1992 · Human RCT
- Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.Eur Neurol · 1987 · Human clinical study
EpitalonCellular aging researchPreclinical literature 6 key studiesResearch & sources
Epitalon (also spelled epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, studied in aging models. Most of its literature comes from one Russian research network.
- Research summary
- Work covers telomerase activity in cell lines, animal aging and cancer models, and small Russian human studies. A 2025 independent study replicated telomere effects in human cell lines.
- Evidence limits
- Cell and animal findings do not establish human longevity or clinical benefit.
- U.S. status · November 7, 2026
- FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 24, 2026 (recommended). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
Identity & technical details
- Primary name
- Epitalon
- Also indexed as
- Epithalon / Ala-Glu-Asp-Gly
- Sequence
- Ala-Glu-Asp-Gly
- Molecular formula
- C14H22N4O9
- Molecular mass
- 390.35 g/mol
- PubChem CID
- 219042
Key studies
- Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.Biogerontology · 2025 · Cell study
- Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence.Int J Mol Sci · 2026 · Review
- Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties.Int J Mol Sci · 2025 · Review
ThymalinThymus-derived material · Immune researchIdentity review required 4 key studiesResearch & sources
Thymalin is a peptide complex originally extracted from calf thymus and used in Russia. It is not one fixed molecule, so composition must be documented case by case.
- Research summary
- Russian clinical and laboratory studies span immunology and aging; recent work is in cell models.
- Evidence limits
- A label reading only “Thymalin” does not establish composition or equivalence to a literature preparation.
- U.S. status · November 7, 2026
- Not FDA-approved. No approved-product or permitted-use claim is made.
Identity & technical details
- Primary name
- Thymalin
- Also indexed as
- Thymalin peptide complex
Key studies
- Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells.Bull Exp Biol Med · 2020 · Cell study
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.Int J Mol Sci · 2022 · Cell study
- Peptides of pineal gland and thymus prolong human life.Neuro Endocrinol Lett · 2003 · Human clinical study
MOTS-cMitochondrial-derived peptide · Cellular energy researchPreclinical literature 6 key studiesResearch & sources
MOTS-c is a 16-residue peptide encoded in mitochondrial DNA. It was first described in 2015 and is studied in cell and animal models of metabolism and exercise.
- Research summary
- Most work is in cells and mice. Human studies so far measure natural MOTS-c levels in blood, for example after exercise; they do not test MOTS-c given as a drug.
- Evidence limits
- Preclinical findings do not establish human safety, clinical effectiveness or a material specification.
- U.S. status · November 7, 2026
- FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 7–5, two abstentions). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
Identity & technical details
- Primary name
- MOTS-c
- Also indexed as
- Mitochondrial open reading frame of the 12S rRNA-c
- Sequence
- MRWQEMGYIFYPRKLR
- Molecular formula
- C101H152N28O22S2
- Molecular mass
- 2174.6 g/mol
- PubChem CID
- 146675088
Key studies
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.Cell Metab · 2015 · Animal and cell study
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.Nat Commun · 2021 · Animal and human study
- MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner.Free Radic Biol Med · 2026 · Animal and cell study
NAD+Cellular energy coenzyme · Not a peptideBiochemical reference 6 key studiesResearch & sources
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in cellular energy and redox reactions, not a peptide. Most human research tests its precursors, NR and NMN.
- Research summary
- Human randomized trials of NR and NMN measure blood NAD+ and metabolic markers. A 2026 Nature Metabolism study compared three precursors head to head.
- Evidence limits
- Raising blood NAD+ is not the same as a clinical benefit, and precursor studies do not describe NAD+ itself given directly.
- U.S. status · November 7, 2026
- No therapeutic or approved-product claim is made.
Identity & technical details
- Primary name
- NAD+
- Also indexed as
- Nicotinamide adenine dinucleotide / NAD / Nadide
- PubChem CID
- 5892
Key studies
- Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.Science · 2021 · Human RCT
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled trial.Geroscience · 2023 · Human RCT
- The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease.Cell Metab · 2022 · Human RCT · phase 1